Mitchall G. Clark, Chief R & QA Officer at Atara Biotherapeutics, Inc. (ATRA), sold 7,829 shares at $46.19 ($362K) on 2015-08-17, disclosed to the SEC on 2015-08-19.
Scheduled sale ($362k) by Chief R & QA Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ATRA | SELL | 2018-04-03 | $898K | — | Filing → |
| ATRA | SELL | 2018-03-28 | $3.8M | — | Filing → |
| ATRA | SELL | 2017-11-17 | $47K | — | Filing → |